Compass Minerals International Inc. press release

Lifshitz Law PLLC Announces Investigations of Autodesk, Inc. (NASDAQ: ADSK), Lincoln National Corporation (NYSE: LNC), Akero Therapeutics, Inc. (NASDAQ: AKRO), and Compass Minerals International, Inc. (NYSE: CMP)

2024-06-26

NYSE - New York Stock Exchange · Salt · Potash · Magnesium · United States · Legal Matters

NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Lifshitz Law Firm, P.C.

Autodesk, Inc. (NASDAQ:ADSK)

Lifshitz Law PLLCannounces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose material information that: (1) Autodesk, Inc. lacked adequate internal controls as a result of issues with its free cash flow and non-GAAP operating margin practices; and (2) as a result, the Company's statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.

If you are an ADSK investor, and would like additional information about our investigation, please complete the Information Request Formor contact Joshua Lifshitz, Esq.by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

Lincoln National Corporation (NYSE:LNC)

Lifshitz Law PLLCannounces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose material information that: (i) the Company was experiencing a decline in its variable universal life insurance ("VUL") business; (ii) the goodwill associated with the life insurance business was overstated; (iii) the Company's policy lapse assumptions were outdated; (iv) the Company's reserves were overstated; (v) the Company's reported financial results and financial statements were misstated; and (vi) as a result of the foregoing, the Company's positive statements about its business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you are a LNC investor, and would like additional information about our investigation, please complete the Information Request Formor contact Joshua Lifshitz, Esq.by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

Akero Therapeutics, Inc. (NASDAQ:AKRO)

Lifshitz Law PLLCannounces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose material information that: (i) approximately 20% of the patients enrolled in its SYMMETRY study had cryptogenic cirrhosis and did not have definitive NASH at baseline; (ii) the cryptogenic cirrhotic patients included in the SYMMETRY study did not have biopsy-proven compensated cirrhosis due to definitive NASH; (iii) the results from the cryptogenic cirrhosis patients were to be excluded from the calculation of the NASH resolution secondary endpoints; (iv) Akero had introduced a confounding factor into the SYMMETRY study's design, materially influencing the study's potential results and increasing the risks that the study would fail to meet its primary endpoint; (v) the SYMMETRY study did not align with U.S. Food & Drug Administration guidance for testing a drug in treating NASH cirrhotics because Akero had not ruled out potential causes of each patient's cirrhosis other than NASH; and (vi) consequently, Akero had materially misrepresented the nature of the SYMMETRY trial, its usefulness in supporting any new drug application, the likelihood that the SYMMETRY trial would be successful as measured by its primary endpoint, and the likelihood that EFX would become a commercial treatment for NASH cirrhotics.

If you are an AKRO investor, and would like additional information about our investigation, please complete the Information Request Formor contact Joshua Lifshitz, Esq.by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

Compass Minerals International, Inc. (NYSE:CMP)

Lifshitz Law PLLCannounces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose material information that: (i) Compass Minerals overstated the likelihood that it would be awarded a renewed U.S. Forest Service contract for the use of its proprietary magnesium chloride-based aerial fire retardants for the 2024 fire season, as a result of safety issues presented by its fire retardant; (ii) Compass Minerals materially overstated the extent to which testing had confirmed that its fire retardants were safe; and (iii) as a result, the Company's statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.

If you are a CMP investor, and would like additional information about our investigation, please complete the Information Request Formor contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

_ATTORNEY ADVERTISING._© 2024 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516) 493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

CONTACT: Joshua M. Lifshitz, Esq. Lifshitz Law PLLC Phone: 516-493-9780 Facsimile: 516-280-7376 Email: info@lifshitzlaw.com

SOURCE: Lifshitz Law Firm, P.C.

View the original press releaseon accesswire.com